Predict your next investment

Xios Therapeutics company logo
HEALTHCARE | Biotechnology
xiostx.com

See what CB Insights has to offer

Founded Year

2015

Stage

Unattributed - II | Alive

Total Raised

$7M

Last Raised

$1M | 3 yrs ago

About Xios Therapeutics

Xios Therapeutics is a biotechnology company developing novel small molecule therapeutics capable of preventing tumors from evading the immune system.

Xios Therapeutics Headquarter Location

100 Beaver Street

Waltham, Massachusetts, 02453,

United States

617-937-2300

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Xios Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Xios Therapeutics is included in 3 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

B

Biopharmaceuticals

5,880 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,604 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Xios Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Xios Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.